Human hepatitis B immunoglobulin (pH4, Sichuan Yuanda Shuyang Pharmaceutical)

乙型肝炎人免疫球蛋白（ph4，四川远大蜀阳药业）

Report date: 2022/03/16 17:41:31

Base Information

Drug NameHuman hepatitis B immunoglobulin (pH4, Sichuan Yuanda Shuyang Pharmaceutical)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin
Mechanisms of ActionImmunomodulators
TargetsNot applicable
Therapy Area/IndicationsHepatitis B
Global Approved IndicationsHepatitis B
Approved Indications in ChinaHepatitis B
Original Approved Country/TerritoryMainland China
Original Approved Date2008/01/01
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesYuanda Shuyang Life Sciences (Chengdu) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesYuanda Shuyang Life Sciences (Chengdu) Co Ltd
Inactive CompaniesN/A
Active IndicationsHepatitis B
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A